Atomo Diagnostics

We are a global company. From our research, development and corporate office in Sydney, Australia; with production capabilities in the U.S.A. and manufacture and distribution in South Africa - we are Atomo.

📣 New report now available online 📣 The Kirby Institute produces Annual Surveillance Reports focusing on the incidence of Blood Borne Viruses (BBVs) and Sexually Transmissible Infections (STIs) in Australia. However, culturally and linguistically diverse (CALD) populations have not been covered explicitly in these reports. This enhanced report from The Kirby Institute is the first to specifically endeavour to report on #BBVs and #STIs among people from CALD backgrounds in Australia.   Ela Naruka | Richard Gray | Jonathan King | Dr Laila Khawar | Skye McGregor | UNSW Medicine & Health   Read the report in full here: https://lnkd.in/gYygnnCx

We’re excited to announce that Atomo Diagnostics will be attending the Australian Pharmacy Professional Conference (APP 2025) on the Gold Coast from March 20-23. As Australia’s largest pharmacy conference, APP is a key event for industry leaders, innovators, and healthcare professionals to connect and drive the future of pharmacy. For Atomo, this is a valuable opportunity to expand our domestic footprint, engage with pharmacy professionals, and showcase how our innovative rapid diagnostic solutions can support better healthcare delivery across Australia. We look forward to meaningful discussions, new partnerships, and contributing to the advancement of accessible, high-quality diagnostics. If you’re attending, we’d love to connect! Come and visit us at Booth 216! See you on the Gold Coast!

Some of the incredible women from Atomo Diagnostics’ Australian team attended Medical Technology Association of Australia (MTAA)’s International Women’s Day: March Forward event in Sydney on Wednesday, March 5. The theme for the event was March Forward – For ALL Women and Girls, recognising that true progress means lifting up the next generation of young women within the industry. As we approach International Women’s Day this Saturday, we celebrate the contributions of women in MedTech and reaffirm our commitment to fostering diversity, innovation, and leadership in the industry.

ICYMI: CEO and Managing Director John Kelly and Financial Controller Suzy Elhlou presented Atomo Diagnostics' H1 FY25 results this morning, Monday March 3. If you would like to catch up on the presentation, please click the link below. https://lnkd.in/gBHqAABE

Atomo Diagnostics is pleased to announce the release of our H1 FY2025 Results Presentation. CEO John Kelly and Financial Controller Suzy Elhlou will host a webinar this coming Monday, March 3 at 11:00AM AEDT to provide shareholders and other interested parties with a summation of the results. To register for the webinar, please click the link below. https://lnkd.in/gPmQ5JAW

Pitt Street Research initiates coverage on Atomo Diagnostics, a company with unique 'user-friendly' Rapid Diagnostic Tests (RDTs). The finger-prick blood-based tests have several advantages including fast results, improved performance and accuracy. The company has for several years commercialised RDTs for HIV/AIDs and has grown its revenues from this indication nine-fold since COVID-19. Since AT1's 2020 IPO, its shares have underperformed for a few reasons, including the reduced levels of COVID testing after 2022, the perception that blood-based diagnostic tests are being superseded by swab testing, and the perception that HIV is less of a problem now that therapies exist. Even though HIV is less deadly, there is still demand for testing, with governments actively procuring them to support national at-home testing programs. And even though Atomo's total revenue was inflated by Covid, its non-COVID revenues are several times ahead of pre-pandemic levels. Moreover, the company is at a pivotal point where it is building a more comprehensive pipeline. It has expanded registration of its HIV Self-Tests to more than 30 countries, is introducing a first in-market rapid test to detect active syphilis, developed with a partner, a new product for blood pregnancy testing that recently obtained CE Mark Approval, and expanded its OEM test cassette supply business so that its Pascal device supports US FDA 510k approval. We value Atomo at $63.4m in a base case and $90.9m in an optimistic case, equating to $0.10 per share and $0.143 per share under the current number of shares on issue but amount to $0.056 per share and $0.08 per share when accounting for future dilution. We see potential for Atomo’s shares to re-rate as the company takes a larger share of the market, commercialises its pipeline of new products and as it transitions to profitability. Please note that this is general advice only and a report Pitt Street has been commissioned to be prepared. Pitt Street directors own shares in Atomo. Please see page 23 for the key risks and the final page for the full general advice warning, disclosure and disclaimers. John Kelly Marc Kennis Stuart Roberts John Keith Paul Kasian Deborah Neff Cheri Walker #atomo #atomodiagnostics #hiv #hivaids #hivtests #hivtestkits #hivtests #selftesting #medtech #medtechstocks #healthcare #healthcarestocks #stocks #shares #equities #investing #investors #equitymarkets #sharemarket #stockmarket #asx #asxstocks #asxshares  

ICYMI: Atomo CEO John Kelly presented Atomo Diagnostics' Q2 FY25 update on Thursday, January 30. To watch the replay of the webinar, click the link below. https://lnkd.in/gjMT5rEa

This coming week from February 3-5, Atomo CEO John Kelly will be heading over to Dubai for the annual Informa Markets #Medlab Middle East Summit. Medlab Middle East is the leading laboratory and diagnostics exhibition and conference in the Middle East, bringing together global experts, industry leaders, and innovative companies in the field of medical laboratory technology. Held annually in Dubai, UAE, Medlab serves as a hub for professionals in clinical diagnostics, laboratory management, and medical research. The event features a large-scale exhibition showcasing cutting-edge diagnostic equipment, laboratory instruments, and healthcare solutions from top manufacturers and suppliers worldwide. It also hosts a multi-track conference program, offering deep insights into laboratory medicine, digital pathology, molecular diagnostics, and regulatory advancements. Medlab Middle East attracts a diverse audience, including laboratory professionals, healthcare providers, policymakers, and business executives, making it a key platform for networking, business development, and knowledge sharing. It plays a crucial role in advancing laboratory medicine and improving healthcare outcomes across the Middle East and beyond. If you are attending Medlab and would like to meet with John to discuss how Atomo's cutting edge rapid diagnostic solutions can help elevate your organisation's products, please reach out on LinkedIn or email info@atomodiagnostics.com See you in Dubai!

Atomo Diagnostics is pleased to present its results for Q2, FY25.   Chief Executive Officer John Kelly will discuss key highlights from the quarter and provide an overview of the Company's focus for 2025.   The presentation will run for approximately 20 minutes with a 10-minute Q&A session to follow.   Please submit all questions in advance to investorqueries@atomodiagnostics.com    Date: Thursday, 30 January Time: 1:30pm AEDT Duration: Approximately 30 minutes To register for the webinar, click the link below. https://lnkd.in/gEms9CVu